文献速递浆细胞疾病

多发性骨髓瘤基因组图谱分析揭示新的预后标志物和疾病亚组

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.
PubMed 文献 · Leukemia · 2018-05-22

该研究利用二代测序(NGS)对418例初诊多发性骨髓瘤患者的基因组图谱进行表征,并与预后和分类相关联。易位和拷贝数异常(CNA)在定义基因型和预后方面比基因突变更具主导作用。研究识别了已知和新的独立预后标志物,并基于突变总数和CNA数量/类型观察到对生存有不同影响的患者聚类,提示扩展基因型可能改善疾病分类和预后。

要点

  • 易位和拷贝数异常(CNA)对多发性骨髓瘤基因型和预后的贡献大于基因突变。
  • 在硼替佐米和免疫调节剂治疗且长期随访的患者中识别出已知和新的独立预后标志物,包括PRDM1基因缺失等具有背景特异性预后价值的事件。
  • 基于突变总数和CNA数量/类型可分患者聚类,不同聚类对生存影响不同,提示扩展基因型可能改善疾病分类和预后。

核心结论

  • 多发性骨髓瘤初诊时的扩展基因型可能改善疾病分类和预后判断。

研究设计与样本

  • 研究利用二代测序(NGS)对418例初诊多发性骨髓瘤患者的基因组图谱进行表征,并与预后和分类相关联。

主要发现

  • 易位和拷贝数异常(CNA)在定义每个病例的基因型和预后方面比基因突变贡献更突出。
  • 在蛋白酶体抑制剂和免疫调节剂治疗且长期随访的患者队列中,识别出已知和新的独立预后标志物,包括PRDM1基因缺失等具有背景特异性预后价值的事件。
  • 基于突变总数和CNA数量/类型观察到患者聚类,不同聚类对生存有不同影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In multiple myeloma, next-generation sequencing (NGS) has expanded our knowledge of genomic lesions, and highlighted a dynamic and heterogeneous composition of the tumor. Here we used NGS to characterize the genomic landscape of 418 multiple myeloma cases at diagnosis and correlate this with prognosis and classification. Translocations and copy number abnormalities (CNAs) had a preponderant contribution over gene mutations in defining the genotype and prognosis of each case. Known and novel independent prognostic markers were identified in our cohort of proteasome inhibitor and immunomodulatory drug-treated patients with long follow-up, including events with context-specific prognostic value, such as deletions of the PRDM1 gene. Taking advantage of the comprehensive genomic annotation of each case, we used innovative statistical approaches to identify potential novel myeloma subgroups. We observed clusters of patients stratified based on the overall number of mutations and number/type of CNAs, with distinct effects on survival, suggesting that extended genotype of multiple myeloma at diagnosis may lead to improved disease classification and prognostication.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Bolli N, Biancon G, Moarii M, et al. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018. PMID: 29789651. doi:10.1038/s41375-018-0037-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。